Scinai Immunotherapeutics (SCNI) Non-Current Debt (2018 - 2026)

Scinai Immunotherapeutics (SCNI) has 9 years of Non-Current Debt data on file, last reported at $287000.0 in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Debt changed N/A year-over-year to $287000.0; the trailing twelve-month figure through Mar 2026 stood at $287000.0 (changed N/A YoY), and the FY2025 full-year result was $294000.0, up 13.08% from the prior year.
• Non-Current Debt eased to $287000.0 in Q1 2026, from $294000.0 in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $23.3 million in Q2 2023 to a low of $260000.0 in Q4 2024.
• A 5-year average of $13.0 million and a median of $18.6 million in 2023 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt plunged 99.98% in 2022 and surged 56.92% in 2023, its largest moves.
• Tracing SCNI's Non-Current Debt over 5 years: stood at $20.1 million in 2022, then decreased by 3.56% to $19.4 million in 2023, then sank by 98.66% to $260000.0 in 2024, then gained by 13.08% to $294000.0 in 2025, then decreased by 2.38% to $287000.0 in 2026.
• Business Quant data shows SCNI's Non-Current Debt at $287000.0 in Q1 2026, $294000.0 in Q4 2025, and $293000.0 in Q2 2025.